research Baricitinib-loaded separable microneedle array patch (S-MAP) based on hyaluronic acid for alopecia areata therapy
The new microneedle patch effectively treats alopecia areata with fewer side effects than oral medication.
Search
for
Sort by
Research
570-600 / 1000+ resultsresearch Delayed granulomatous eruption of the nose associated with ruxolitinib
Ruxolitinib can cause a delayed skin reaction on the nose.
research Acitretin-Altered Squamous Cell Carcinoma
research Unravelling a novel role for cannabidivarin in the modulation of subventricular zone postnatal neurogenesis
Cannabidivarin (CBDV) may help brain cell growth and survival through the TRPV1 receptor.
research Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer
Sacituzumab Govitecan is effective for certain breast cancers but requires careful management of side effects.
research A machine learning and network framework to discover new indications for small molecules
A machine learning model called CATNIP can predict new uses for existing drugs, like using antidepressants for Parkinson's disease and a thyroid cancer drug for diabetes.
research Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
research Peer Review #2 of "Nature-derived lignan compound VB-1 exerts hair growth-promoting effects by augmenting Wnt/β-catenin signaling in human dermal papilla cells (v0.1)"
A natural compound called VB-1 can help promote hair growth by boosting a specific cell signal in human skin cells.
research A plain language summary of quality of life with sacituzumab govitecan treatment in the TROPiCS-02 study in participants with breast cancer (HR-positive/HER2-negative)
Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.
research Nilontinib induced keratosis pilaris atrophicans
Nilotinib can cause skin issues like red bumps and hair loss.
research Alopecia areata and tofacitinib: a prospective multicenter study from a Saudi population
Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
research Inhibitory effect of M50054, a novel inhibitor of apoptosis, on anti-Fas-antibody-induced hepatitis and chemotherapy-induced alopecia
M50054 may help treat hepatitis and hair loss from chemotherapy.
research An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review.
An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.
research Low-dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost-saving regimen
Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
research A Therapeutic Role for Survivin in Mitigating the Harmful Effects of Ionizing Radiation
Inducing survivin in normal tissues can protect against radiation damage.
research A new era for alopecia areata: New treatments and improved knowledge of the condition
Baricitinib effectively promotes long-term hair regrowth in alopecia areata patients.
research Epidermal growth factor receptor mutant T790M-L858R-V948R inhibitor from Calophyllum inophyllum L. leaf as potential non-small cell lung cancer drugs
A compound from Calophyllum inophyllum L. leaf may help treat non-small cell lung cancer.
research LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.
research Erlotinib-Induced Skin Inflammation Is IL-1 Mediated in KC-Tie2 Mice and Human Skin Organ Culture
Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.
research Ponatinib-induced pityriasis rubra pilaris-like adnexal dysmaturation: A case report
Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
research BH09 Patient experience of off-label Janus kinase inhibitor use for alopecia areata in a cohort of 34 patients from a single UK practitioner: exploring changing trends in healthcare provision and access to drug treatments
Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
research ¿Novedad o prudencia? El delicado equilibrio en la actualización farmacológica
New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
research Transarterial chemoembolization (TACE) combined with donafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A real-world clinical study.
The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.
research Recovery of nail dystrophy potential new therapeutic indication of tofacitinib
Tofacitinib may help treat nail dystrophy, especially when other treatments fail.
research Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound?
Nirmatrelvir/Ritonavir treatment may lead to a weaker immune response to COVID-19, but doesn't affect the chance of rebound.
research Clinical response to adjunctive platelet-rich plasma injections in a patient with alopecia universalis on oral tofacitinib
A woman with severe hair loss saw significant hair regrowth after adding platelet-rich plasma injections to her treatment with tofacitinib.
research 455 Molecular correlation with clinical outcomes in an open label clinical trial of oral tofacitinib in patients with alopecia areata
Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.
research Subclinical, early hair regrowth in alopecia areata patients under treatment with baricitinib detected by line‐field confocal optical coherence tomography evaluation
Baricitinib helps with early hair regrowth in people with alopecia areata.
research Remarkable Improvement of Nail Changes in Alopecia Areata Universalis with 10 Months of Treatment with Tofacitinib: A Case Report
A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.
research Acute and 30-day oral toxicity studies of a novel coccidiostat – ethanamizuril
Ethanamizuril is safe for rats at 20 mg/kg feed, but higher doses cause hair loss, organ changes, and liver, kidney, and lung damage.